Antiviral therapy of varicella-zoster virus infections

Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis

Volumn , Issue , 2007, Pages 1175-1191

  Gnann, John W ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929286923     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545313.066     Document Type: Chapter

References (105)

1. Acosta, E. P. and Balfour, H. H., Jr. (2001). Acyclovir for treat-ment of postherpetic neuralgia: Efficacy and pharmacokinet-ics. Antimicrob. Agents Chemother., 45, 2771-2774.
2. Acosta, E. P. and Fletcher, C. V. (1997). Valacyclovir. Ann. Pharma-cother., 31, 185-191.
3. Arbeter, A. M., Granowetter, L., Starr, S. E. et al. (1990). Immuniza-tion of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy. Pediatrics, 85, 338-344.
4. Arvin, A. M. (2002). Antiviral therapy for varicella and herpes zoster. Semin. Pediatr. Infect. Dis., 13, 12-21.
5. Asano, Y., Yoshikawa, T., Suga, S. et al. (1993). Postexposure prophy-laxis of varicella in family contacts by oral acyclovir. Pediatrics, 92, 219-222.
6. Balfour, H. H., Bean, B., Laskin, O. L. et al. (1983). Acyclovir halts pro-gression of herpes zoster in immunocompromised patients. N. Engl. J. Med., 308, 1448-1453.
7. Balfour, H. H., Kelly, J. M., Suarez, C. S. et al. (1990). Acyclovir treat-ment of varicella in otherwise healthy children. J. Pediatr., 116, 633-639.
8. Balfour, H. H., Jr., Rotbart, H. A., Feldman, S. et al. (1992). Acyclovir treatment of varicella in otherwise healthy adolescents. The Collaborative Acyclovir Varicella Study Group. J. Pediatr., 120 (4, Part 1), 627-633.
9. Beutner, K. R., Friedman, D. J., Forszpaniak, C. et al. (1995). Valaci-clovir compared with acyclovir for improved therapy for her-pes zoster in immunocompetent adults. Antimicrob. Agents Chemother., 39, 1546-1553.
10. Bodsworth, N. J., Boag, F., Burdge, D. et al. (1997). Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. J. Infect. Dis., 176, 103-111.
11. Boivin, G., Edelman, C. K., Pedneault, L. et al. (1994). Phenotypic and genotypic characterization of acyclovir-resistant varicella zoster viruses isolated from persons with AIDS. J. Infect. Dis., 170, 68-75.
12. Bowsher, D. (2003). Factors influencing the features of posther-petic neuralgia and outcome when treated with tricyclics. Eur. J. Pain, 7, 1-7.
13. Breton, G., Fillet, A. M., Katlama, C. et al. (1998). Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: Results of foscarnet therapy. Clin. Infect. Dis., 27, 1525-1527.
14. Centers for Disease Control and Prevention (1996). Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Weekly Rep., 45, 1-36.
15. Cobo, L. M., Foulks, G. N., Liesgang, T. et al. (1986). Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthal-mology, 93, 763-770.
16. Colin, J., Prisant, O., Cochener, B. et al. (2000). Comparison of the efficacy and safety of valaciclovir and acyclovir for the treat-ment of herpes zoster ophthalmicus. Ophthalmology, 107, 1507-1511.
17. Dahl, H., Marcoccia, J., and Linde, A. (1997). Antigen detection: The method of choice in comparison with virus isolation and serology for laboratory diagnosis of herpes zoster in human immunodeficiency virus-infected patient. J. Clin. Microbiol., 35, 345-349.
18. Davies, P. S. and Galer, B. S. (2004). Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs, 64, 937-947.
19. De La Blanchardiere, A., Rozenberg, F., Caumes, E. et al. (2000). Neurological complications of varicella-zoster virus infec-tion in adults with human immunodeficiency virus infection. Scand. J. Infect. Dis., 32, 263-269.
20. Degreef, H. and the Famciclovir Herpes Zoster Study Group (1994). Famciclovir, a new oral antiherpes drug: Results of the First controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patient. Int. J. Antimicrob. Agents, 4, 241-246.
21. Dodd, D. A., Burger, J., Edwards, K. M. et al. (2001). Varicella in a pediatric heart transplant population on nonsteroid mainte-nance immunosuppression. Pediatrics, 108, E80.
22. Dunkle, L. M., Arvin, A. M., Whitley, R. J. et al. (1991). A controlled trial of acyclovir for chickenpox in normal children. N. Engl. J. Med., 325, 1539-1544.
23. Dworkin, R. H. and Schmader, K. E. (2003). Treatment and pre-vention of postherpetic neuralgia. Clin. Infect. Dis., 36, 877-882.
24. Dworkin, R. H., Boon, R. J., Griffin, D. R. et al. (1998). Postherpetic neuralgia: Impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J. Infect. Dis., 178 (Suppl. 1), S76-S80.
25. Dworkin, R. H., Perkins, F. M., and Nagasako, E. M. (2000). Prospects for the prevention of postherpetic neuralgia in herpes zoster patients. Clin. J. Pain, 16 (Suppl. 2), S90-100.
26. Dworkin, R. H., Corbin, A. E., Young, J. P., Jr. et al. (2003). Prega-balin for the treatment of postherpetic neuralgia: A random-ized, placebo-controlled trial. Neurology, 60, 1274-1283.
27. Furth, S. L. and Fivush, B. A. (2002). Varicella vaccination in pediatric kidney transplant candidates. Pediatr. Transpl., 6, 97-100.
28. Galindez, O. A., Sabates, N. R., Whitacre, M. W. et al. (1996). Rapidly progressive outer retinal necrosis caused by varicella zoster virus in a patient infected with human immunodeficiency virus. Clin. Infect. Dis., 22, 149-151.
29. Gershon, A. A., Mervish, N., LaRussa, P. et al. (1997). Varicella-zoster virus infection in children with underlying human immunod-eficiency virus infection. J. Infect. Dis., 176, 1496-1500.
30. Glantz, J. C. and Mushlin, A. I. (1998). Cost-effectiveness of routine antenatal varicella screening. Obstet. Gynecol., 91, 519-528.
31. Gnann, J. W., Jr. (2002). Varicella-zoster virus: Atypical presentations and unusual complications. J. Infect. Dis., 186 (Suppl. 1), S91-S98.
32. Gnann, J. W., Jr. and Whitley, R. J. (2002). Clinical practice. Herpes zoster. N. Engl. J. Med., 347, 340-346.
33. Gnann, J. W., Crumpacker, C. S., Lalezari, J. P. et al. (1998). Sorivu-dine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: Results from a randomized, controlled clinical trial. Antimi-crob. Agents Chemother., 42, 1139-1145.
34. Gross, G., Schofer, H., Wassilew, S. et al. (2003). Herpes zoster guide-line of the German Dermatology Society (DDG). J. Clin. Virol., 26, 277-289; discussion 291-293.
35. Haake, D. A., Zakowski, P. C., Haake, D. L. et al. (1990). Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: Retrospective controlled study and review. Rev. Infect. Dis., 12, 788-798.
36. Harding, S. P. and Porter, S. M. (1991). Oral acyclovir in herpes zoster ophthalmicus. Curr. Eye Res., 10 (Suppl.), 177-182.
37. Harger, J. H., Ernest, J. M., Thurnau, G. R. et al. (2002). Frequency of congenital varicella syndrome in a prospective cohort of 347 pregnant women. Obstet. Gynecol., 100, 260-265.
38. Harrison, R. A., Soong, S., Weiss, H. L. et al. (1999). A mixed model for factors predictive of pain in AIDS patients with herpes zoster. J. Pain Symptom Managem., 17, 410-417.
39. Hata, A., Asanuma, H., Rinki, M. et al. (2002). Use of an inac-tivated varicella vaccine in recipients of hematopoietic-cell transplants. N. Engl. J. Med., 347, 26-34.
40. Hellden, A., Odar-Cederlof, I., Diener, P. et al. (2003). High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: An observa-tional study. Nephrol. Dial. Transpl., 18, 1135-1141.
41. Herbort, C. P., Buechi, E. R., Piguet, B. et al. (1991). High dose oral acyclovir in acute herpes zoster ophthalmicus: The end of the corticosteroid era. Curr. Eye Res., 10 (Suppl.), 171-175.
42. Hoang-Xuan, T., Buchi, E. R., Herbot, C. P. et al. (1992). Oral acyclovir for herpes zoster ophthalmicus. Ophthalmology, 99, 1062-1071.
43. Huff, J. C., Bean, B., Balfour, H. H. et al. (1988). Therapy of herpes zoster with oral acyclovir. Am. J. Med., 85 (Suppl. 2A), 84-88.
44. Jacobson, M. A., Berger, T. G., Fikrig, S. et al. (1990). Acyclovir-resistant varicella zoster virus infection after chronic oral acy-clovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med., 112, 187-191.
45. Johnson, R. W. (2002). Consequences and management of pain in herpes zoster. J. Infect. Dis., 186 (Suppl. 1), S83-S90.
46. Johnson, R. W. and Dworkin, R. H. (2003). Treatment of her-pes zoster and postherpetic neuralgia. Br. Med. J., 326, 748-750.
47. Keam, S. J., Chapman, T. M., and Figgitt, D. P. (2004). Brivudin (bro-movinyl deoxyuridine). Drugs, 64, 2091-2097.
48. Kotani, N., Kushikata, T., Hashimoto, H. et al. (2000). Intrathe-cal methylprednisolone for intractable postherpetic neuralgia. N. Engl. J. Med., 343, 1514-1519.
49. Levin, M. J., Dahl, K. M., Weinberg, A. et al. (2003a). Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immuno-suppressed child. J. Infect. Dis., 188, 954-959.
50. Levin, M. J., Smith, J. G., Kaufhold, R. M. et al. (2003b). Decline in varicella-zoster virus (VZV)-specific cell-mediated immu-nity with increasing age and boosting with a high-hose VZV vaccine. J. Infect. Dis., 188, 1336-1344.
51. Liesegang, T. J. (1999). Varicella zoster viral disease. Mayo Clin. Proc., 74, 983-998.
52. Lionnet, F., Pulik, M., Genet, P. et al. (1996). Myelitis due to varicella-zoster virus in 2 patients with AIDS: Successful treatment with acyclovir. Clin. Infect. Dis., 22, 138-140.
53. Ljungman, P. (2001). Prophylaxis against herpesvirus infections in transplant recipients. Drugs, 61, 187-196.
54. Ljungman, P., Lonnqvist, B., Ringden, O. et al. (1989). A randomized trial of oral versus intravenous acyclovir for treatment of her-pes zoster in bone marrow transplant recipients. Bone Marrow Transpl., 4, 613-615.
55. Lundgren, G., Wilecek, H., Lonnqvist, B. et al. (1985). Acyclovir pro-phylaxis in bone marrow transplant recipients. Scand. J. Infect. Dis., 47 (Suppl. 7), 137-144.
56. McKendrick, M. W., McGill, J. I., White, J. E. et al. (1986). Oral acy-clovir in acute herpes zoster. Br. Med. J., 293, 1529-1532.
57. Meyers, J. D., Wade, J. C., Shepp, D. H. et al. (1984). Acyclovir treat-ment of varicella-zoster virus infection in the compromised host. Transplantation, 37, 571-574.
58. Morton, P. and Thomson, A. N. (1989). Oral acyclovir in the treat-ment of herpes zoster in general practice. N Z Med. J., 102, 93-95.
59. Nagasako, E. M., Johnson, R. W., Griffin, D. R. et al. (2002). Rash severity in herpes zoster: Correlates and relationship to pos-therpetic neuralgia. J. Am. Acad. Dermatol., 46, 834-839.
60. Nathwani, D., Maclean, A., Conway, S. et al. (1998). Varicella infec-tions in pregnancy and the newborn. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J. Infect., 36 (Suppl. 1), 59-71.
61. Nyerges, G., Meszner, Z., Gyarmati, E. et al. (1988). Acyclovir pre-vents dissemination of varicella in immunocompromised chil-dren. J. Infect. Dis., 157, 309-313.
62. Opstelten, W., van Wijck, A. J., and Stolker, R. J. (2004). Interven-tions to prevent postherpetic neuralgia: Cutaneous and percu-taneous techniques. Pain, 107, 202-206.
63. Ormerod, L. D., Larkin, J. A., Margo, C. A. et al. (1998). Rapidly progressive herpetic retinal necrosis: A blinding disease char-acteristic of advanced AIDS. Clin. Infect. Dis., 26, 34-45.
64. Oxman, M. N. et al. (2005). A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med., 352, 2271-2284.
65. Palay, D. A., Sternberg, P., Jr., Davis, J. et al. (1991). Decrease in the risk of bilateral acute retinal necrosis by acyclovir therapy. Am. J. Ophthalmol., 112, 250-255.
66. Perren, T. J., Powles, R. L., Easton, D. et al. (1988). Prevention of herpes zoster in patients by long-term oral acyclovir after allo-genic bone marrow transplantation. Am. J. Med., 85 (Suppl. 2A), 99-101.
67. Perry, C. M. and Wagstaff, A. J. (1995). Famciclovir: A review of its pharmacological properties and therapeutic efficacy in her-pesvirus infections. Drugs, 50, 396-415.
68. Poscher, M. E. (1994). Successful treatment of varicella-zoster virus meningoencephalitis in patients with AIDS: Report of 4 cases and review. AIDS, 8, 1115-1117.
69. Prober, C. G., Kirk, L. E., and Keeney, R. E. (1982). Acyclovir therapy of chickenpox in immunocompromised children: A collabora-tive study. J. Pediatr., 101, 622-625.
70. Raja, S. N., Haythornthwaite, J. A., Pappagallo, M. et al. (2002). Opi-oids versus antidepressants in postherpetic neuralgia: A ran-domized, placebo-controlled trial. Neurology, 59, 1015-1021.
71. Reiff-Eldridge, R., Heffner, C. R., Ephross, S. A. et al. (2000). Monitor-ing pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: A pharmaceutical company commitment. Am. J. Obstet. Gynecol., 182, 159-163.
72. Rice, A. S. and Maton, S. (2001). Gabapentin in postherpetic neuralgia: A randomized, double blind, placebo controlled study. Pain, 94, 215-224.
73. Rowbotham, M., Harden, N., Stacey, B. et al. (1998). Gabapentin for the treatment of postherpetic neuralgia: A randomized con-trolled trial. J. Am. Med. Assoc., 280, 1837-1842.
74. Sabatowski, R., Galvez, R., Cherry, D. A. et al. (2004). Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomised, placebo-controlled clinical trial. Pain, 109, 26-35.
75. Schmader, K. (2001). Herpes zoster in older adults. Clin. Infect. Dis., 32, 1481-1486.
76. Serota, F. T., Starr, S. E., Bryan, C. K. et al. (1982). Acyclovir treatment of herpes zoster infections: Use in children undergoing bone marrow transplantation. J. Am. Med. Assoc., 247, 2132-2135.
77. Severson, E. A., Baratz, K. H., Hodge, D. O. et al. (2003). Herpes zoster ophthalmicus in Olmsted County, Minnesota: Have systemic antivirals made a difference? Arch. Ophthalmol., 121, 386-390.
78. Shafran, S. D., Tyring, S. K., Ashton, R. et al. (2004). Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: A randomized, multicenter, double-blind clinical trial. J. Clin. Virol., 29, 248-253.
79. Shepp, D. H., Dandliker, P. S., and Meyers, J. D. (1986). Treatment of varicella-zoster infection in severely immunocompromised patients: A randomized comparison of acyclovir and vidara-bine. N. Engl. J. Med., 314, 208-212.
80. Stacey, B. R. and Glanzman, R. L. (2003). Use of gabapentin for postherpetic neuralgia: Results of two randomized, placebo-controlled studies. Clin. Ther., 25, 2597-2608.
81. Stranska, R., Schuurman, R., de Vos, M. et al. (2004). Routine use of a highly automated and internally controlled real-time PCR assay for the diagnosis of herpes simplex and varicella-zoster virus infections. J. Clin. Virol., 30, 39-44.
82. Suga, S., Yoshikawa, T., Ozaki, T. et al. (1993). Effect of oral acyclovir against primary and secondary viraemia in incubation period of varicella. Arch. Dis. Child., 69, 639-642.
83. Tyring, S., Barbarash, R. A., Nahlik, J. E. et al. (1995). Famci-clovir for the treatment of acute herpes zoster: Effects on acute disease and post-herpetic neuralgia: A randomized, double-blind, placebo-controlled trial. Ann. Int. Med., 123, 89-96.
84. Tyring, S. K., Beutner, K. R., Tucker, B. A. et al. (2000). Antivi-ral therapy for herpes zoster: Randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocom-petent patients 50 years and older. Arch. Fam. Med., 9, 863-869.
85. Tyring, S., Belanger, R., Bezwoda, W. et al. (2001a). A randomized, double-blind trial of famciclovir versus acyclovir for the treat-ment of localized dermatomal herpes zoster in immunocom-promised patients. Cancer Invest., 19, 13-22.
86. Tyring, S., Engst, R., Corriveau, C. et al. (2001b). Famciclovir for ophthalmic zoster: A randomised aciclovir controlled study. Br. J. Ophthalmol., 85, 576-581.
87. Tyring, S. K., Baker, D., and Snowden, W. (2002). Valacyclovir for herpes simplex virus infection: Long-term safety and sustained efficacy after 20 years’ experience with acyclovir. J. Infect. Dis., 186 (Suppl. 1), S40-S46.
88. Wagstaff, A. J. and Bryson, H. M. (1994). Foscarnet: A reappraisal of its antiviral activity, pharmacokinetic properties and thera-peutic use in immunocompromised patients with viral infec-tions. Drugs, 48, 199-226.
89. Wallace, M. R., Bowler, W. A., and Murray, N. B. (1992). Treatment of adult varicella with oral acyclovir. Ann. Intern. Med., 117, 358-363.
90. Wassilew, S. W. and Wutzler, P. (2003a). Oral brivudin in com-parison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: Results of a randomized, double-blind, multicentered study. Antiviral Res., 59, 49-56.
91. Wassilew, S. W. and Wutzler, P. (2003b). Oral brivudin in comparison with acyclovir for herpes zoster: A survey study on postherpetic neuralgia. Antiviral Res., 59, 57-60.
92. Watson, B., Seward, J., Yang, A. et al. (2000). Postexposure effective-ness of varicella vaccine. Pediatrics, 105, 84-88.
93. Watson, C. P. and Babul, N. (1998). Efficacy of oxycodone in neu-ropathic pain: A randomized trial in postherpetic neuralgia. Neurology, 50, 1837-1841.
94. Watson, C. P., Vernich, L., Chipman, M. et al. (1998). Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial. Neurology, 51, 1166-1171.
95. Whitley, R. J. and Gnann, J. W. (1992). Acyclovir: A decade later. N. Engl. J. Med., 327, 782-789.
96. Whitley, R. J., Gnann, J. W., Hinthorn, D. et al. (1992). Disseminated herpes zoster in the immunocompromised host: A compara-tive trial of acyclovir and vidarabine. J. Infect. Dis., 165, 450-455.
97. Whitley, R. J., Weiss, H., Gnann, J. W. et al. (1996). Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann. Intern. Med., 125, 376-383.
98. Whitley, R. J., Weiss, H. L., Soong, S. J. et al. (1999). Herpes zoster: Risk categories for persistent pain. J. Infect. Dis., 179, 9-15.
99. Wilkins, E. G., Leen, C. L., McKendrick, M. W. et al. (1998). Manage-ment of chickenpox in the adult. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J. Infect., 36 (Suppl. 1), 49-58.
100. Wood, M. J., Ogan, P. H., McKendrick, M. W. et al. (1988). Efficacy of oral acyclovir treatment of acute herpes zoster. Am. J. Med., 85 (Suppl. 2A), 79-83.
101. Wood, M. J., Johnson, R. W., McKendrick, M. W. et al. (1994). A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N. Engl. J. Med., 330, 896-900.
102. Wood, M. J., Kay, R., Dworkin, R. H. et al. (1996). Oral acyclovir ther-apy accelerates pain resolution in patients with herpes zoster: A meta-analysis of placebo-controlled trials. Clin. Infect. Dis., 22, 341-347.
103. Wood, M. J., Shukla, S., Fiddian, A. P. et al. (1998). Treatment of acute herpes zoster: Effect of early (48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain. J. Infect. Dis., 178 (Suppl. 1), S81-S84.
104. Zaal, M. J., Volker-Dieben, H. J., and D'Amaro, J. (2003). Visual prog-nosis in immunocompetent patients with herpes zoster oph-thalmicus. Acta Ophthalmol. Scand., 81, 216-220.
105. Zaia, J. A., Levin, M. J., Preblud, S. R. et al. (1983). Evaluation of varicella-zoster immune globulin: Protection of immunosup-pressed children after household exposure to varicella. J. Infect. Dis., 147, 737-743.